Berlin clinical research institute specialising in cardiovascular risk prediction, integrated care for multimorbid patients, and hospital-embedded clinical trial implementation.
Helios Health Institute is a clinical research institute embedded within the HELIOS hospital network — one of Germany's largest private hospital operators — giving it direct access to real-world patient populations and clinical implementation pathways that purely academic institutions lack. Their work centers on cardiovascular disease: specifically, building personalized risk prediction models for sudden cardiac death survivors and developing integrated care frameworks for elderly patients managing multiple conditions simultaneously. They translate complex clinical evidence into practical decision-support tools that physicians can use at the point of care. Their distinctive contribution to research consortia is the combination of hospital-scale patient data access, implementation expertise, and health-economic evaluation of care pathways.
PROFID (2020–2026) targets personalised risk stratification and prevention of sudden cardiac death in post-myocardial infarction patients, the institute's largest funded project at EUR 973,388.
EHRA-PATHS (2021–2026) addresses multimorbidity, polypharmacy, and interdisciplinary care coordination in elderly atrial fibrillation patients.
PROFID explicitly targets the creation of a clinical decision tool for risk stratification, indicating methodological expertise in translating predictive models into clinical workflows.
EHRA-PATHS incorporates self-management support, patient empowerment, and quality-of-life outcomes as core components of its tailored care intervention.
Cost-effectiveness is listed as a key theme in EHRA-PATHS, suggesting the institute contributes economic evaluation capabilities alongside clinical research.
Their first H2020 engagement (PROFID, 2020) was tightly focused on a single high-stakes clinical event: preventing sudden cardiac death in post-myocardial infarction patients through personalised risk prediction. The second project (EHRA-PATHS, 2021) marked a clear shift toward broader complexity — elderly patients with atrial fibrillation carrying multiple simultaneous conditions, polypharmacy risks, and the need for interdisciplinary coordination across healthcare settings. This trajectory moves from acute single-disease prediction toward chronic, multimorbid patient management with strong emphasis on system-level factors like integrated care delivery, patient agency, and cost sustainability within healthcare systems.
The institute is moving toward real-world complexity: from predicting individual cardiac events to managing elderly patients with multiple overlapping conditions — a direction that aligns with Europe's aging population challenge and growing policy interest in integrated, cost-effective chronic disease management.
Helios Health Institute has participated exclusively as a consortium partner across both projects, never serving as coordinator — consistent with a specialist contributor that brings clinical data access and implementation expertise rather than administrative project leadership. With 37 unique partners across 16 countries in just two projects, they work in large, internationally diverse consortia, suggesting a preference (or selection) for ambitious multi-site clinical studies that require real hospital network access. This profile makes them an attractive specialist node rather than a hub, meaning they are best approached as a clinical implementation partner rather than a lead organisation.
Despite only two projects, the institute has built a notably wide network of 37 unique partners spanning 16 countries — an average of roughly 18–19 consortium members per project, indicating involvement in large, pan-European clinical trials or implementation studies. No geographic clustering is visible from the data, pointing to broad European reach rather than a regional focus.
What separates Helios Health Institute from independent research institutes or university hospital departments is its backing by the HELIOS hospital group, which operates over 80 hospitals across Germany and Spain — providing access to patient cohorts at a scale most academic partners cannot match. For consortium builders, this means real-world clinical validation and implementation pathways are built into the partnership from day one, not added as an afterthought. Their focus on both risk prediction tools AND integrated care delivery positions them at the rare intersection of clinical informatics, cardiology, and health systems research.
